UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 11, 2022 Date of Report (date of earliest event reported)

The Oncology Institute, Inc.

(Exact name of registrant as specified in its charter)

001-39248 (Commission File Number) 84-3562323 (I.R.S. Employer Identification Number)

Delaware (State or other jurisdiction of incorporation or organization)

18000 Studebaker Rd, Suite 800 Cerritos, California 90703 (Address of principal executive offices and zip code) (562) 735-3226

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities regist	ered pursuant to Section 12(b) of the Act:	
Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value \$0.001	TOI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of \$11.50 per share	TOIIW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

On March 11, 2022, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the year ended December 31, 2021 and certain other financial information. A copy of the presentation is furnished hereto as Exhibit 99.1, which are incorporated by reference herein.

Item 7.01. Regulation FD Disclosure

On March 11, 2022, in conjunction with the slide presentation of its financial results, the Company provided updates regarding the Company's business and guidance for the upcoming year ending December 31, 2022. The information provided above in "Item 2.02 - Results of Operations and Financial Condition" of this Current Report on Form 8-K ("Current Report") is incorporated by reference into this Item 7.01.

The information contained in Items 2.02 and 7.01 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section.

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.	Description
99.1	Slide presentation issued by The Oncology Institute, Inc. on March 11, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 11, 2022


The Oncology Institute, Inc.

By:

/s/ Brad Hively Brad Hively Name: Title: Chief Executive Officer



Investor Presentation March 2022



Note: (1) Compared to average Per Member Per Month costs in our primary geographies (2) Based on cash basis unaudited financials

DS0	Shouldn't we keep these metrics as of year-end? If so, this would be 10. Diona Simoneit, 2022-03-05T23:05:04.740
RM0 0	based on Daniel's comments Rajovic, Mark, 2022-03-07T02:11:26.302
DS0 1	Latham advised to keep consistent with 10-K. This needs to be 10. Diona Simoneit, 2022-03-07T17:41:08.557
DS1	Shouldn't we keep these metrics as of year-end? If so, this would be 80+. Diona Simoneit, 2022-03-05T23:05:15.961
RM1 0	based on Daniel's comments Rajovic, Mark, 2022-03-07T02:11:23.214
DS1 1	Latham advised to keep consistent with 80+ This needs to be 10. Diona Simoneit, 2022-03-07T17:41:18.559
DS2	Update to \$203 Diona Simoneit, 2022-03-05T23:06:04.498
RM2 0	updated Rajovic, Mark, 2022-03-07T02:10:54.004
DS3	Update to 25.1 Diona Simoneit, 2022-03-05T23:06:13.570
RM3 0	updated Rajovic, Mark, 2022-03-07T02:10:58.845

Investment Highlights

A market leader in value-based oncology currently disrupting a massive, unaffordable and inefficient oncology marke

Highly tailored and integrated offering supported by both providers and payers as incentives are aligned

Tech-driven care delivery method to deliver better patient outcomes and higher satisfaction ratings

Scalable, replicable model with significant whitespace growth opportunities in a fragmented M&A environment

Capital Light Organic Growth



Rising Cost of Oncology Care is a Massive Problem in the U.S.







The Oncology Institute of Hope & Innovation

Sources: Cancer Epidemiology, Biomarkers & Prevention – American Association For Cancer Research, July 2020; National Center for Health Statistics; IQVIA Institute; National Health Expenditure Data – CMS; Spending on Health: Latest Trends – OECD, June 2018.

We Are Disrupting the Status Quo in Cancer Care



We Are Shifting the Market to Value Based Oncology Care




Gain Share Contracts

Gain Share Contracts Offer TOI an Entry Point with Payors in New Markets

- Gain share contracts offer payors an alternative to full capitation, with incentives for TOI to drive reductions in cost of care and improvements in qua
 of care
- Typically structured with an upside-only share of savings generated on patients seen by TOI relative to a benchmark
- Creative solution for risk-bearing primary care groups that aren't delegated for contracting
- Can include quality incentives for TOI to further improve patient care and lower overall cost
- Acts as a stepping stone to a broader capitation relationship as TOI demonstrates the value of its model of care

Illustrative Gain Share Contract Structure






We Use Multiple Levers to Reduce Cost of Care

ſ	Where We Focus	Savings
Treatments	 Reduce practice pattern variability Access to clinical trials in the community Vertical integration of pharmacy 	>25% Reduction in
Palliative Care	 Providers trained in advanced care planning Close coordination between network providers 	Experience in relatively low cost California market
Symptom Management	 Algorithm driven action plan 24/7 Health Care Coach Patient education and engagement 	
The Oncology Institut of Hope & Innovation		Satisfaction, Health Status, Healthcare Use, and Total Costs; Journal Of Oncology Practice; August 16, 2019.

Our Care Model is Hard to Replicate



Our Results are Peer-Reviewed and Published



Our Patient-Centric Focus Drives High Levels of Satisfactio





"Thank you all for helping me through this life test...From the front desk to the specialist – when it comes to cancer, you are all needed and appreciated; your kindness and selflessness makes a world of difference to the patients and their families." – Lynwood Clinic Patient "Awesome place, from the support staff and Dr. Morrison. He was the BEST! Would highly recommend this clinic to everyone who needs it."

- Downey Clinic Patient

Thousands of same-day patient surveys text and email.

Overall survey average 4.5/5 across all sites over 12 months.

Survey feedback loop to operations managers drives service excellence.


"I am very thankful and happy to have found his group. Dr. Baghian and staff are kind, compassionate, and knowledgeable. Everyone I have interacted with has made me feel as though they truly care about making sure I receive quality care in a timely manner. Exceptional!" — Riverside Clinic Patient

The Oncology Institute of Hope & Innovation

RM1

DS0	Should we be including 2022 data? If ok, we should not include March as the month isn't over. Diona Simoneit, 2022-03-05T23:08:25.668
RM0 0	l would suggest removing march Rajovic, Mark, 2022-03-07T02:14:26.745
DS0 1	Latham advised to not share any Q1 data. Please cut-off at 12/31/21. Diona Simoneit, 2022-03-07T17:43:24.864
RM0 2	do you have the underlying chart? i did not create this. thanks Rajovic, Mark, 2022-03-07T18:18:30.981
RM1	Can we produce prior 12 months? from Jan 21 ro Dec 21 Rajovic, Mark, 2022-03-08T21:10:38.082

Our Technology Platform is Purpose Built for Oncology Care







Multiple Levers to Sustain Long Term Growth Trajectory



Financial Overview



Recent Highlights

- Ended 2021 at with approximately 1.6 million lives under value-based contracts
- Cared for over 51,000 unique patients in 2021 and had over 230,000 patient visits at owned clinics
- Commenced four new capitated payor contracts in California since mid-2021
- Acqui-hires of three medical oncology practices in the Los Angeles, CA market in the fourth quarter of 2021
- Hired 12 new affiliated providers in the fourth quarter of 2021, representing 18% growth over the prior year peric
- Acquired first radiation oncology practice, based in Los Angeles, CA in the fourth quarter of 2021
- Opened 54th clinic site in February 2022 in Lakeland, FL, an increase of 14 clinics from year end 2020

TOI is leading the market towards value-based oncology care



Fourth Quarter Financial Highlights

- Total revenue was \$52 million, a 6.8% increase from the prior year period
- Gross profit was \$8 million, a 23.1% decrease from the prior year period
- Net loss was \$(10) million, compared to \$(5) DS2 ion in the prior year period
- Adjusted EBITDA was \$(5) million, compared to \$2 DS3 ion in the prior year period
- The fourth quarter of 2021 included \$8 million of public company expenses
- Ending cash balance of \$115 million and no debt as of December 31, 2021





The Oncology Institute of Hope & Innovation

Note: Adjusted EBITDA is a non-GAAP measure. For a discussion and reconciliation to the nearest GAAP measure please see Slide 20 of this presentation

DS0	Change to \$49 Diona Simoneit, 2022-03-07T17:56:09.733
RM0 0	updatedupdated Rajovic, Mark, 2022-03-07T18:17:33.445
RM0 1	updated Rajovic, Mark, 2022-03-07T18:17:38.335
DS1	Change to \$52 Diona Simoneit, 2022-03-07T17:56:23.720
RM1 0	updated Rajovic, Mark, 2022-03-07T18:15:37.972
DS2	Changed to \$(5) so we are consistent throughout with no decimal points. Diona Simoneit, 2022-03-07T17:57:45.736
DS3	Changed to \$2 for consistency

D23	Changed to \$2 for consistency	
	Diona Simoneit, 2022-03-07T17:58:18.275	



Key Metrics

DS0

DS0	Can we round the dollar amounts to whole dollars to be consistent? Diona Simoneit, 2022-03-07T17:59:25.732
RM0 0	updated Rajovic, Mark, 2022-03-07T18:17:55.786
DS1	Can we round the dollar amounts to whole dollars to be consistent? Diona Simoneit, 2022-03-07T17:59:31.308

RM10 updated

Rajovic, Mark, 2022-03-07T18:17:51.396

Guidance

	2022 Guidance
Revenue	\$270 to 310 million, representing approximately 33% to 53% growth over 2021 revenue
Gross Profit	\$50 to 60 million
Adjusted EBITDA	\$(20) to (25) million
Lives at Year End	1.75 million to 2.0 million lives, representing approximately 9% to 25% growth over year-end 2021 lives

Updated Guidance Drivers

- Strong year-over-year revenue and lives growth expected
- · Continued focus on pipeline execution and network expansion to deliver care under value-based contracts
- Growth in California and new market penetration in Florida and Texas
- · Gain sharing contracts and higher mix of FFS-reimbursement is expected to produce lower revenue and gross profit
- TOI's public company costs are higher than initially projected, mainly due to D&O insurance cost




The Oncology Institute of Hope & Innovation

RM0

RM0

note form LW to TOI: Add a bullet on the defaulting customer that was described in the press release/script? Rajovic, Mark, 2022-03-08T00:09:49.573

Net Income to Adjusted EBITDA Reconciliation



DS0

DS0	Can we round these to whole dollars in millions to be consistent with the rest of the financials presented? Diona Simoneit, 2022-03-07T18:01:30.828
RM0 0	l have no problem doing this but some categories would round to 0 (Interest, taxes, Mgmt. Fees, Other, Acquisiton costs)
	Rajovic, Mark, 2022-03-07T18:20:36.651

Net Income to Adjusted EBITDA Reconciliation Footnotes

(1) During the year ended December 31, 2021, non-cash addbacks were primarily comprised of a \$4,957 gain on debt extinguishment and bad debt recoveries, net of \$417 partial offset by deferred rent of \$109 other miscellaneous charges of \$149. During the year ended December 31, 2020, non-cash addbacks were primarily comprised of a \$7,5C impairment of notes receivable (as described further below), \$4,233 of bad debts write-offs, and \$239 of other miscellaneous charges.

(2) Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practice:

(3) Consulting and legal fees were comprised of a subset of the Company's total consulting and legal fees during the years and quarters ended December 31, 2021 and 2020, an related to certain advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.

(4) Other, net is comprised of severance expenses resulting from cost rationalization programs of \$127 and \$278, as well as temporary labor of \$1,182 and \$1,862 recruitin expenses to build out corporate infrastructure of \$1,275 and 1,289 and other miscellaneous charges of \$130 and \$0 during the years ended December 31, 2021 and 2020 respectively. During the years ended December 31, 2021 and 2020 such expenses were partially offset by \$1,023 and \$978, respectively, of stimulus funds received under th CARES Act.


(5) Adjusted EBITDA was impacted by \$1,800,000 revenue reduction during the fourth quarter of 2021 related to a payor not paying according to their contract.

Note: Costs related to directors and officers insurance, de novo clinics and new providers have not been added back to arrive at Adjusted EBITDA.



Strong Unit Economics Drives Increasing Profitability

Embedded Gross Margin Expansion Potential as TOI Scales





The Oncology Institute of Hope & Innovation

Note: (1) Advanced Practice Providers (APPs) include Physician Assistants and Nurse Practitioners; (2) Each pod is an operational unit consisting of 2-5 clinics, grouped together based on geographic proximity and visit volume. This analysis was performed in 2020.

RM0 note from LW to TOI: Do you want to retain this 30% target margin going forward? This type of disclosure is often not included once public. Rajovic, Mark, 2022-03-08T00:10:37.197

Forward Looking Statements

This presentation includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "pelipininary," "believe," "may," "will," "estimate," "continue," "anticip "intend," "expect," "should," "would," "plan," "project," "predict," "potential," "guidance," "approximately," "seem," "seek," "future," "outlook," and similar expressions that predict or indica events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and fore revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of The Oncology Institute, Inc. ("TOI") and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumsta difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of TOI. These forward-looking statements are subject t number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which TOI may become a party or governmental investigations to which TOI may become subject that could interrupt or limit TOI's operations, result in adverse judgments, settlements or fines and create negative publicity; changes in TOI's clients' preferences, pro and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect TOI; failure to continue to meet stock exchange standards; the impact of COVID-19 on the TOI's business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC. If the risks materialize or assumptions pr incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that TOI does not presently know or that TO currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect T(plans or forecasts of future events and views as of the date of this press release. TOI anticipates that subsequent events and developments will cause TOI's assessments to change. does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing TOI's assessments any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements

Financial Information; Non-GAAP Financial Measures:

Some of the financial information and data contained in this presentation, such as Adjusted EBITDA, have not been prepared in accordance with United States generally accept accounting principles ("GAAP"). TOI believes that the use of Adjusted EBITDA provides an additional tool to assess operational performance and trends in, and in comparing our finar measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. TOI's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, finar measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be reco the Company's financial statements. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this presentation conjunction with TOI's financial statements and the related notes thereto.

